Combination therapies that inhibit the FGFR-mitochondrial metabolism-Notch1 axis may then limit the growth of tumour stem cell subpopulations and enhance the anti-tumour effects of TORC1/2 inhibitors (78). The gene discussed is NOTCH1; the disease is neoplasm.